Use of recovery animals for human safety assessment across the pharmaceutical development package

2018 ◽  
Vol 295 ◽  
pp. S223-S224
Author(s):  
F. Sewell ◽  
N. Gellatly ◽  
H. Prior
1997 ◽  
Vol 85 (4) ◽  
pp. 842-846 ◽  
Author(s):  
James C. Eisenach ◽  
David D. Hood ◽  
Regina Curry

1997 ◽  
Vol 85 (4) ◽  
pp. 842-846 ◽  
Author(s):  
James C. Eisenach ◽  
David D. Hood ◽  
Regina Curry

2006 ◽  
Vol 36 (1) ◽  
pp. 1-7 ◽  
Author(s):  
Neil G. Carmichael ◽  
Hugh A. Barton ◽  
Alan R. Boobis ◽  
Ralph L. Cooper ◽  
Vicki L. Dellarco ◽  
...  

2012 ◽  
Vol 211 ◽  
pp. S176 ◽  
Author(s):  
Richard Billington ◽  
Tina Mehta ◽  
Richard Lewis ◽  
Bennard van Raavenzway ◽  
Christian Strupp ◽  
...  

2019 ◽  
Vol 661 ◽  
pp. 294-305 ◽  
Author(s):  
Giuseppe Roberto Pisaturo ◽  
Maurizio Righetti ◽  
Claudio Castellana ◽  
Michele Larcher ◽  
Andrea Menapace ◽  
...  

1995 ◽  
Vol 21 (1) ◽  
pp. 87-107 ◽  
Author(s):  
A.L. Kraus ◽  
I.C. Munro ◽  
J.C. Orr ◽  
R.L. Binder ◽  
R.A. Leboeuf ◽  
...  

2017 ◽  
Vol 45 (7) ◽  
pp. 1004-1011 ◽  
Author(s):  
Xiaoting Wang ◽  
Hervé Lebrec

A continuing education course entitled “What You Always Wanted to Know About Immunotoxicology in Pharmaceutical Development…But Were Afraid to Ask” was offered at the Society of Toxicologic Pathology (STP) 36th annual symposium in Montreal. This article summarizes some key points made during the presentation dedicated to immunophenotyping. It describes how clusters of differentiation (CDs) are well-defined antigens used to characterize cell subsets, and how lymphocyte subsets in humans and different rodent and nonrodent species can be defined by detection of various combinations of CDs. It provides an overview of immunophenotyping study design considerations and applications to safety assessment.


Sign in / Sign up

Export Citation Format

Share Document